ESWL for Distal Ureteric Stone: Supine Versus Prone
Launched by QUEEN MARY HOSPITAL, HONG KONG · Nov 21, 2014
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a treatment called extracorporeal shockwave lithotripsy (ESWL) for kidney stones, specifically focusing on two different positions: lying on your back (supine) versus lying on your stomach (prone). Traditionally, patients have been treated while lying prone, but some people find this position uncomfortable or difficult due to health issues. The trial aims to compare these two positions to see if lying on your back can lead to better outcomes, particularly a higher chance of being free of stones after treatment.
To participate in the trial, you need to be an adult (18 years or older) with a specific type of kidney stone that is at least 3mm in size. You cannot have certain medical conditions, such as severe bleeding issues or active infections, that would prevent safe treatment. If you join the study, you will be randomly assigned to one of the two positions for ESWL and monitored for a couple of hours after the procedure. You'll receive pain relief if needed, and follow-up X-rays will check if any stones remain after two weeks. The trial is currently looking to enroll 130 patients, and you can choose to leave the study at any time while still receiving your regular medical care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients, over 18 years of age, with distal ureteric stones with stone size of ≥3mm on kidney-ureter-bladder (KUB) X-ray who opted for ESWL treatment
- Exclusion Criteria:
- • Patients who are unable to provide consent
- • radiolucent stones
- • active urinary tract infections
- • pregnancy
- • uncontrolled hypertension
- • uncontrolled bleeding tendencies
- • severe skeletal malformations
- • arterial aneurysms within the vicinity of the stone (such as iliac artery aneurysms)
- • unable to assume the appropriate position (prone or supine) for ESWL
- • solitary kidneys
- • transplanted kidneys
- • presence of ureteric stents
About Queen Mary Hospital, Hong Kong
Queen Mary Hospital, located in Hong Kong, is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative clinical research. As a prominent teaching hospital affiliated with the University of Hong Kong, it integrates cutting-edge medical practices with rigorous scientific inquiry. The hospital is dedicated to improving patient outcomes through a diverse range of clinical trials that encompass various therapeutic areas, leveraging its state-of-the-art facilities and multidisciplinary expertise. Queen Mary Hospital aims to contribute to global medical knowledge while ensuring the highest standards of patient care and safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , China
Patients applied
Trial Officials
Brian Ho, MBBS
Principal Investigator
Queen Mary Hospital, Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials